文献速递前列腺癌

血尿男性中前列腺癌患病率:系统评价与Meta分析

Prevalence of prostate cancer in men with haematuria: a systematic review and meta-analysis.
PubMed 文献 · BJU Int · 2023-01-30

该系统评价与Meta分析检索MEDLINE、Ovid和Google Scholar,纳入65项研究(42项进入Meta分析),共18 752名血尿男性。合并前列腺癌患病率为3.0%(95%CI 2.0-4.1%);肉眼血尿者5.9%(95%CI 2.9-9.9%;n=265/5373),镜下血尿者1.4%(95%CI 0.8-2.2%;n=71/6642)。作者认为血尿男性前列腺癌患病率可观,建议将直肠指检和前列腺特异性抗原检测作为所有血尿男性的标准流程。

要点

  • 血尿男性合并前列腺癌患病率为3.0%(95%CI 2.0-4.1%)。
  • 肉眼血尿者患病率5.9%(95%CI 2.9-9.9%;n=265/5373)。
  • 镜下血尿者患病率1.4%(95%CI 0.8-2.2%;n=71/6642)。

核心结论

  • 作者认为血尿男性中前列腺癌患病率可观,直肠指检和前列腺特异性抗原检测应成为所有血尿男性的标准流程,尤其是肉眼血尿男性。

研究设计与样本

  • 系统评价与Meta分析,按PROSPERO注册方案(CRD42022299383)执行,2021年12月检索MEDLINE、Ovid和Google Scholar,由两名独立研究者筛选文献。
  • 纳入关于成年男性(≥18岁)血尿与前列腺癌的研究,共筛选4252条标题和摘要、全文评估350项研究,最终纳入65项研究,其中42项进入Meta分析,共18 752名血尿男性。

主要发现

  • 血尿男性合并前列腺癌的合并患病率为3.0%(95%CI 2.0-4.1%)。
  • 肉眼血尿男性合并前列腺癌的合并患病率为5.9%(95%CI 2.9-9.9%;n=265/5373)。
  • 镜下血尿男性合并前列腺癌的合并患病率为1.4%(95%CI 0.8-2.2%;n=71/6642)。

临床怎么用

  • 作者建议将直肠指检和前列腺特异性抗原检测作为所有血尿男性的标准流程,尤其是肉眼血尿男性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the prevalence of prostate cancer in men attending evaluation for haematuria, as this could help healthcare providers to determine whether men with haematuria should have prostate examinations performed. METHODS: The study was performed according to a pre-specified protocol uploaded to the International Prospective Register of Systematic Reviews (PROSPERO; CRD42022299383). A systematic search of MEDLINE, Ovid and Google Scholar was performed in December 2021. Two independent researchers evaluated all titles, available abstracts, and full texts. We included studies on adult men (aged ≥18 years) describing haematuria and prostate cancer. RESULTS: We screened 4252 titles and abstracts when available and assessed 350 studies in full text. In total, 65 studies were included and 42 was summarised in a meta-analysis. In total, 18 752 men with haematuria were included, and the pooled prevalence (95% confidence interval [CI]) of prostate cancer was 3.0% (2.0-4.1%). In men with macroscopic haematuria, the pooled prevalence (95% CI) of prostate cancer was 5.9% (2.9-9.9%; n = 265/5373). In men with microscopic haematuria, the pooled prevalence (95% CI) of prostate cancer was 1.4% (0.8-2.2%; n = 71/6642). CONCLUSION: Our findings indicate that the prevalence of prostate cancer is considerable in men attending evaluation for haematuria. Therefore, digital rectal examination and prostate-specific antigen measurement should become a standard procedure for all men with haematuria, especially for men with macroscopic haematuria.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Hansen RS, Biørn SH, Birk-Korch JB, et al. Prevalence of prostate cancer in men with haematuria: a systematic review and meta-analysis. BJU Int. 2023. PMID: 36522728. doi:10.1111/bju.15950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。